Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8145437 | 0.82 | — | — | |
| SCHEMBL12522843 | 0.80 | ALDH1A1 (0.45) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL12452968 | 0.78 | HDAC1 (0.40) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL10025450 | 0.78 | ALDH1A1 (0.36) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL12522824 | 0.76 | HDAC1 (0.58) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL12299145 | 0.76 | ALDH1A1 (0.36) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL10058185 | 0.76 | ALDH1A1 (0.36) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL10025462 | 0.76 | ALDH1A1 (0.39) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL2436714 | 0.74 | ALDH1A1 (0.36) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 | |
| SCHEMBL10059031 | 0.74 | ALDH1A1 (0.36) | ALDH1A1HDAC1HDAC8HDAC6PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729060-B2 | Macrocyclic polyoxazole compounds and use thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729060-B2 | Macrocyclic polyoxazole compounds and use thereof | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-05-20 | — | — | US | disclosed |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2011-09-22 | — | — | US | disclosed |
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | NIH - DEITR | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230531-A1 | THERAPEUTIC COMPOUNDS | MCL1, MKI67, NCL | ALDH1A1 499/4885HDAC1 114/4885HDAC8 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.